N/A N=110 Relaxing Environment to Lower Anxiety During Onabotulinum Toxin Chemodenervation of the Bladder
Anxiety · Pain · Burnout, Professional
Primary: Mean Change in Visual Analog Scale (VAS) Anxiety Scores — -13.8; -4.7 mm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity
Overactive Detrusor
Primary: Mean Peak Detrusor Pressures — 58; 31 cm H2O
Phase 3 N=172 Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction
Neurogenic Urinary Bladder
Primary: Number of Patients With Detrusor Leak Point Pressure (LPP) < 40 cm H2O — 23; 23; 28; 34 participants — p=1.00
Phase 2 N=76 Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
Detrusor Underactivity · Overactive Bladder
Primary: Changes in the Mean BCI for Male From Baseline to Week 12 — 64.604; 61.339; 75.156; 60.513 Score on a scale — p=<0.001
Phase 2 N=37 Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients
Spinal Cord Injuries
Primary: Net Change of the Urinary Distress Inventory (UDI-6) — 10.4; 7.43 units on a scale
N/A N=18 Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?
Overactive Bladder
Primary: Number of Subjects With Evidence of Bacteria in Urine Sample by Microbiologic Evaluation — 8; 1 participants
Phase 4 N=20 Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
Parkinson's Disease · Neurogenic Bladder · Urinary Incontinence
Primary: Number of Patients Requiring Catheterization for Urinary Retention Secondary to Treatment. — 0 participants
Phase 3 N=114 Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients
Urinary Incontinence
Primary: Change From Baseline in Daily Average Frequency of Daytime Urinary Incontinence Episodes — -1.30; -1.30; -1.34 urinary incontinence episodes per day — p=0.9949
Phase 3 N=76 A Study to Assess the Long Term Effect, Safety and Metabolism of a Solifenacin Liquid Suspension in Participants 5 to 18 Years of Age With Neurogenic Detrusor Overactivity
Neurogenic Detrusor Overactivity
Primary: Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) — 57.2; 59.3 mL — p=<0.001
Phase 2 N=47 Neurogenic Detrusor Overactivity Following Spinal Cord Injury or Multiple Sclerosis
Detrusor Muscle Hyperactivity
Primary: Daily Incontinence Episode Frequency (IEF) — 4.21; 3.33; 3.23; 4.40 episodes per day — p=0.11
Phase 3 N=12 Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.
Urinary Bladder, Neurogenic
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs): Merged Data of Studies A0221047 and A0221109 — 2; 9; 2; 6…
N/A N=40 Study to Determine Effects of Vesicare on Return to Continence Post - Radical Prostatectomy (Part II)
Urinary Incontinence
Primary: Time to Continence — 95 Days to Continence
Phase 3 N=21 Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
Urinary Bladder, Overactive
Primary: Treatment Phase 1 (Treatment Cycle 1)- Change From Baseline in the Daily Average Number of Urinary Incontinence Episodes at Week 6 — -0.18; -3.20 Episodes
N/A N=12 Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder
Multiple Sclerosis · Lower Urinary Tract Symptoms · Neurogenic Bladder
Primary: Change in Blood Oxygen Level Dependent (BOLD) Signals in the Brain After Treatment — 2.6; 2.6; 3.5; 2.6 BOLD Signal Change Derived T-Value — p=0.0012
N/A N=55 Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium
Urinary Incontinence
Primary: Change From Baseline in Anticholinergic Drug Use — 305.21; 199.77 Doses of Anticholinergic Drugs